HDAC6 and infarction: Significant emphasis was placed on the assessment of neurological outcomes as recommended by the STAIR consortium,36,37 rather than focusing solely on infarction size as seen in previous analyses.21 Moreover, the employed modelling approaches enabled us to combine individually presented longitudinal datasets and statistically compare the assess the influence of different doses of HDAC6 inhibitors, and timing of administration, on the several functional outcomes.